新辅助化疗联合保乳手术治疗中晚期乳腺癌临床应用价值.docVIP

新辅助化疗联合保乳手术治疗中晚期乳腺癌临床应用价值【摘要】　目的：探讨新辅助化疗联合保乳手术治疗中晚期乳腺癌的临床疗效。方法：回顾笔者所在医院近年来收治的62例中晚期乳腺癌患者的临床资料，分析新辅助化疗及保乳手术的临床疗效、美容效果及预后。结果：经新辅助化疗治疗后有19例患者符合保乳手术治疗指征，均行保乳手术治疗。术后随访6个月～3年，仅有2例发生肝转移，无乳腺癌复发及死亡病例。结论：术前应用新辅助化疗能有效降低乳腺癌分期，达到保乳手术治疗标准，且术后疗效满意，美容效果好，值得临床推广应用。 【关键词】　新辅助化疗；　乳腺癌；　保乳手术；　 疗效 Clinical Value of Mid-advanced Breast Cancer Treating with Neoadjuvant Chemotherapy Combined with Breast-conserving Surgery/WANG Guo-fang，TANG Min.//Medical Innovation of China，2012，9(25):008-009 【Abstract】　Objective:To investigate the clinical curative effect of mid-advanced breast cancer treating with neoadjuvant chemotherapy combined with breast-conserving surgery.Method:Retrospective analyse the clinical information of 62 cases mid-advanced breast cancer patients treating with preoperative neoadjuvant chemotherapy in author’s hospital，to analyse the clinical curative effect， beauty effect and prognosis.Result:After the neoadjuvant chemotherapy，19 cases had the indicatio curativa of breast-conserving surgery，and all treated with breast-conserving surgery.Follow-up visit 6 months-3 years after the operation，there was no recidivation and died case，and only 2 case appeared hepatic metastases.Conclusion:Preoperative neoadjuvant chemotherapy can reduce the degree of breast cancer，and achieve the breast surgery treatment standards，the clinical curative effect is satisfied，and worthy of clinical application. 【Key words】　Neoadjuvant chemotherapy；　Breast cancer；　Breast-conserving surgery；　Clinical curative effect First-authors address:Daxian Nancheng Community Health Service Center in Sichuan Province，Daxian 635000，China doi：10.3969/j.issn.1674-4985.2012.25.004 乳腺癌是女性常见的恶性肿瘤之一，随着女性生活方式及社会地位的改变，其发病率呈逐年上升趋势，已在女性恶性肿瘤死因中居于首位[1-2]。早期乳腺癌常采用保留乳房手术及术后放疗、化疗、内分泌治疗，并能取得较好的临床疗效[3]。但对于中晚期乳腺癌患者，往往无法达到保乳手术的要求，传统的根治性手术给患者的生理和心理都带来了严重的危害。近年来新辅助化疗联合保乳手术治疗乳腺癌得到了迅速的发展，新辅助化疗能有效缩小肿瘤体积，降低乳腺癌分期，使更多的乳腺癌患者能够接受保乳手术的治疗，并取得了良好的疗效。现回顾分析笔者所在医院2006年1月-2011年6月接受新辅助化疗的62例中晚期乳腺癌患者的临床资料，探讨新辅助化疗的临床疗效，报道如下。 1　资料与方法 1.1